Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same
AssigneeNational Cheng Kung University
InventorChien-Chung Hung
Life of this patent
Estimating the term…
Abstract
The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer stemness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.
Claims9
A method for specifically inhibiting ubiquitin-specific peptidase 24 (USP24) in cancer cells, comprising:
- administering a medicinal composition to the cancer cells which are suspicious of a cancerous or undifferentiated phenotype expressing multidrug resistance, wherein the medicinal composition comprises:
- a chemotherapeutic drug;
- and
- a chemosensitizing agent comprising a ubiquitin-specific peptidase 24 (USP24) inhibitor composition, wherein the USP24 inhibitor composition comprises a short interfering nucleic acid (siNA) and a carbonyl substituted phenyl compound, the siNA is a short interfering ribonucleic acid (siRNA), the siRNA is a short-hairpin USP24 (shUSP24) RNA having a sequence listed as SEQ ID NO:1, the carbonyl substituted phenyl compound has a structure as formula (I-3):
A method for delaying or reversing multidrug resistance in cancers, comprising:
- administering a medicinal composition to cancer cells which are suspicious of a cancerous or undifferentiated phenotype expressing multidrug resistance, wherein the medicinal composition comprises:
- a chemotherapeutic drug;
- and
- a chemosensitizing agent comprising a ubiquitin-specific peptidase 24 (USP24) inhibitor composition, wherein the USP24 inhibitor composition comprises a short interfering nucleic acid (siNA) and a carbonyl substituted phenyl compound, and the siNA is a short interfering ribonucleic acid (siRNA), the siRNA is a short-hairpin USP24 (shUSP24) RNA having a sequence listed as SEQ ID NO:1, and the carbonyl substituted phenyl compound has a structure as formula (I-3):
Dependencies are inferred from the claim text.